PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs AVXL's -3.46%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Cash + STI yoy 1.25-1.5x AVXL's -3.46%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-4.22%
1.25-1.5x AVXL's -2.89%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-17.65%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AVXL and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-47.54%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
≥ 1.5x AVXL's -2.89%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
46.70%
Above 1.5x AVXL's 13.48%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-26.38%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
265.71%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
63.25%
Above 1.5x AVXL's 16.44%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Above 1.5x AVXL's 16.44%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
0.5-0.75x AVXL's -6.30%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
≥ 1.5x AVXL's -4.03%. David Dodd sees stronger capital base growth than competitor.
-4.84%
≥ 1.5x AVXL's -2.89%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both AVXL and the company show zero Total Investments Growth.
-26.37%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
5.01%
1.25-1.5x AVXL's 3.46%. Martin Whitman is wary of heavier net leverage vs. competitor.